Novo’s Saxenda Is Latest Weight Loss Drug to See US Shortage

Novo Nordisk A/S’s drug Saxenda is the latest to hit a shortage, as high demand for weight loss drugs sparks supply snags across the industry.

Saxenda will have limited availability through the end of the year, according to a notice posted Tuesday on a US Food and Drug Administration database.

On a consumer-facing website for the drug, the company said it is still making and shipping Saxenda but warned of issues filling prescriptions “for the remainder of 2023 and beyond.”

“We continue to see demand for Saxenda increase at a substantial rate, resulting in supply interruptions,“ a Novo spokesperson ...